Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

AOS to take Misonix products to eastern Europe

This article was originally published in Clinica

  • News
  • Joseph Harvey  

Executive Summary

Misonix has entered a two-year deal with private German firm Advanced Oncology Systems (AOS) to sell its ultrasonic technology in eastern Europe. The deal sees Wuppertal-based AOS make Misonix’s Sonablate SB500 high-intensity focused ultrasound (HIFU) system, SonaStar ultrasonic surgical aspiration system, BoneScalpel ultrasonic bone cutting system, and its SonicOne ultrasound cleansing and debridement system available in countries such as Hungary, Poland, Romania, Bulgaria, Russia, Ukraine and Georgia. Misonix (Farmingdale, New York) said that sales would be carried out by specialty distributors, while sales made directly to hospitals would be permitted in certain instances. Financial terms of the deal were not disclosed.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

Front Line Medical Technologies Announce CE Mark For COBRA-OS

Recalls Round-Up: Class 1s For BioMérieux, Fresenius, Draeger, More

New Guidance For Breast Cancer Screening Drops Age Of First Scan To 40

CDRH’s AR/VR Home Space Will Serve As An ‘Idea Lab’ For Device Stakeholders

See All
UsernamePublicRestriction

Register

MT042388

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By